• Namita Sood.
• Associate ProfessorThe Ohio State University , Columbus, OH 43210 , USA sood.7@osu.edu.
• Expert Opin Pharmacother. 2014 Dec 1; 15 (18): 2733-9.

IntroductionPulmonary arterial hypertension (PAH) is a serious disease characterized by elevation of pulmonary artery pressures and right ventricular failure. It is a progressive disease with a poor 5-year survival despite recent advances in treatment. Endothelin plays an important role in the development and progression of the disease. Endothelin receptor blockers have been used to treat PAH since 2001. More recently, macitentan was approved for treatment of PAH.Area CoveredThis review covers the preclinical and clinical data on macitentan.Expert OpinionMacitentan is a more potent ERA and has been shown to delay progression of the disease. It does not appear to have any significant hepatotoxicity and has a convenient once-a-day dosing. In the large event driven trial, macitentan significantly reduced morbidity in patients with PAH. It was safe and well tolerated and the benefit was seen in treatment-naïve patients and those already receiving PAH therapy.

23 keywords...

hide…